Organon, the human healthcare business of Akzo Nobel, has signed a collaboration agreement with HUYA Bioscience International to identify new, proprietary biopharmaceuticals or pharmaceutical compounds. As part of this collaboration, Organon has acquired an equity interest in HUYA. Financial details were not disclosed. HUYA identifies, licenses and develops Chinese drug candidates for commercialization in Western markets. HUYA has offices in San Diego and Shanghai. Under the terms of the ag...